Seres Therapeutics (MCRB)
Develops oral bacterial consortia for infection, immune, and inflammatory conditions.
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) IST data support SER-155 as a potential treatment for irEC that may allow patients to continue cancer therapy; Company evaluating irEC clinical development strategy in consultation with KOLs Seres engaging potential partners, seeking capital to advance its SER-155 programs, including for the prevention of bloodstream infections in patients undergoing allo-HCT and those experiencing irEC Seres announces agreement to exit additional leased space early, further reducing ongoing facility-related cash costs, which follows announcement of balance sheet strengthening and facilities cost reduction transactions in June 2026 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported second quarter 2026 financial results and provided business updates.
Seres Therapeutics Posts Early Data for Cancer Therapy Complication
Seres Therapeutics Inc. (NASDAQ:MCRB) on Wednesday reported topline results from an investigator-sponsored trial evaluating SER-155 in patients with immune-related enterocolitis (irEC), with most participants achieving a steroid-free clinical response after treatment.
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases Company pursuing partnerships and other sources of capital to support continued development of pipeline programs including SER-155 in allo-HSCT CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported first quarter 2026 financial results and provided business updates.
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification Presentation selected for DDW 'Poster of Distinction' recognition CAMBRIDGE, Mass.
Seres Therapeutics to Present at CARB-X Investor Day
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany.
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program continue Company to host conference call tomorrow, March 3, at 8:30 am ET CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Richard N.
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following the company's announcement of a strategic shift in its operations.
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company's runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing development of its early-stage live biotherapeutic programs in Inflammatory and immune diseases and supporting the read-out of clinical results from the fully enrolled Investigator-sponsored SER-155 study in immune checkpoint related enterocolitis (irEC), a frequent and severe adverse events in recipients of ICI therapy, expected in early Q2 2026 CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that, following advancement of key startup activities for the SER-155 Phase 2 study in allo-HSCT, including the submission of a final protocol to the FDA, study site evaluation and qualification with its CRO, and manufacturing of Phase 2 study drug substance, Seres is pausing additional investment in that program and will shift its operational focus to high-value earlier-stage pipeline programs while continuing to seek funding for the SER-155 Phase 2 study.
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell?
Shares of Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $15.49 and traded as low as $14.06. Seres Therapeutics shares last traded at $14.31, with a volume of 23,382 shares changing hands. Wall Street Analyst Weigh
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell?
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $16.63 and traded as low as $15.00. Seres Therapeutics shares last traded at $15.18, with a volume of 60,238 shares traded. Wall Street Analyst Weigh In
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report)'s share price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $18.13 and traded as low as $16.80. Seres Therapeutics shares last traded at $17.90, with a volume of 115,995 shares traded. Wall Street Analysts
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m.
Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
Seres Therapeutics, Inc. ( MCRB ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Carlo Tanzi Marella Thorell - Co-CEO, Co-President & CFO Matthew Henn - Executive VP & Chief Scientific Officer Dennis M. Walling - Senior VP of Clinical Development & Head of Clinical Research Teresa Young - Executive VP and Chief Commercial & Strategy Officer Conference Call Participants John Newman - Canaccord Genuity Corp., Research Division Joseph Thome - TD Cowen, Research Division Presentation Operator Good day, everyone, and thank you for standing by.
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these actions and current operating plans, Seres expects to fund operations through Q2 2026 CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2025 financial results and provided business updates.